Skip to Main content Skip to Navigation
Journal articles

Quel avenir en thérapeutique cardiovasculaire pour le monoxyde d’azote et ses dérivés ?

Abstract : Nitric oxide (NO) is involved in the regulation of several physiological processes such as vascular homeostasis. Exogenous NO supply offers major therapeutic interest, especially in the treatment of coronary artery disease, ischemic syndromes and other cardiovascular pathologies. Nevertheless, the administration of NO itself is limited by its short half-life. NO prodrugs have been marketed for decades, e.g. organic nitrates for angina pectoris. These prodrugs display undeniable advantages such as angina crisis relief and preconditioning effect. Nevertheless, they suffer from several drawbacks: toxicity, tolerance, endothelial dysfunction exacerbation. These negative effects are related to massive production of reactive species derived from oxygen or nitrogen, which trigger oxidative and nitrosative stress. New NO donors are under development to overcome those disadvantages, among which the S-nitrosothiols family seems especially promising.
Document type :
Journal articles
Complete list of metadata
Contributor : Cithefor UL Connect in order to contact the contributor
Submitted on : Tuesday, March 22, 2016 - 10:08:41 AM
Last modification on : Friday, September 10, 2021 - 1:04:03 PM




Marianne Parent, François Dupuis, Philippe Maincent, Claude Vigneron, Pierre Leroy, et al.. Quel avenir en thérapeutique cardiovasculaire pour le monoxyde d’azote et ses dérivés ?. Annales Pharmaceutiques Françaises, Elsevier Masson, 2013, 71 (2), pp.84-94. ⟨10.1016/j.pharma.2012.12.004⟩. ⟨hal-01291781⟩



Record views